Expect delays in clinical trials unrelated to Covid-19, says former FDA chief Scott Gottlieb

With much of the focus on Covid-19 vaccines and treatments, there's growing concern of a possible slowdown in the FDA's drug review process for treatment of other illnesses. Dr. Scott Gottlieb, member of the boards of Pfizer and biotech company Illumina and former FDA commissioner, joins "Squawk Box" to discuss.
Fri, May 29 20206:47 AM EDT